SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) valuation after new CEO appointment and SYH2085 influenza trial approval
The latest move at CSPC Pharmaceutical Group (SEHK:1093) blends leadership change with pipeline progress, as the company installs a new CEO and secures trial approval for its SYH2085 influenza candidate.
See our latest analysis for CSPC Pharmaceutical Group.
The market seems to like this mix of fresh leadership and R&D momentum, with CSPC Pharmaceutical Group's 1 day share price return of 7.64 percent and 7 day share price return of 20.65 percent pushing the stock to HK$8.88. This backs up an...